TY - JOUR
T1 - Innovations in infectious disease testing
T2 - Leveraging COVID-19 pandemic technologies for the future
AU - Tran, Nam K.
AU - Albahra, Samer
AU - Rashidi, Hooman
AU - May, Larissa
N1 - Funding Information:
Nam Tran is a consultant for Roche Diagnostics / Roche Molecular Systems. UC Davis Health is a Roche Diagnostics Molecular Center of Excellence. Nam Tran, Hooman Rashidi, and Samer Albahra are co-owners of MILO-ML, LLC, and co-inventors of the Machine Intelligence Learning Optimizer platform. Larisssa May has served a consultant on SARS-CoV-2 testing for Roche Diagnostics/Roche Molecular Systems, Cepheid, Abbott Laboratories. Nam Tran, Hooman Rashidi, and Larissa May are investigators developing the MALDI-TOF-MS COVID-19 testing platform.
Publisher Copyright:
© 2021 The Canadian Society of Clinical Chemists
PY - 2022
Y1 - 2022
N2 - Innovations in infectious disease testing have improved our abilities to detect and understand the microbial world. The 2019 novel coronavirus infectious disease (COVID-19) pandemic introduced new innovations including non-prescription “over the counter” infectious disease tests, mass spectrometry-based detection of COVID-19 host response, and the implementation of artificial intelligence (AI) and machine learning (ML) to identify individuals infected by the severe acute respiratory syndrome - coronavirus – 2 (SARS-CoV-2). As the world recovers from the COVID-19 pandemic; these innovative solutions will give rise to a new era of infectious disease tests extending beyond the detection of SARS-CoV-2. To this end, the purpose of this review is to summarize current trends in infectious disease testing and discuss innovative applications specifically in the areas of POC testing, MS, molecular diagnostics, sample types, and AI/ML.
AB - Innovations in infectious disease testing have improved our abilities to detect and understand the microbial world. The 2019 novel coronavirus infectious disease (COVID-19) pandemic introduced new innovations including non-prescription “over the counter” infectious disease tests, mass spectrometry-based detection of COVID-19 host response, and the implementation of artificial intelligence (AI) and machine learning (ML) to identify individuals infected by the severe acute respiratory syndrome - coronavirus – 2 (SARS-CoV-2). As the world recovers from the COVID-19 pandemic; these innovative solutions will give rise to a new era of infectious disease tests extending beyond the detection of SARS-CoV-2. To this end, the purpose of this review is to summarize current trends in infectious disease testing and discuss innovative applications specifically in the areas of POC testing, MS, molecular diagnostics, sample types, and AI/ML.
KW - Artificial intelligence
KW - Direct to consumer
KW - Machine learning
KW - Mass spectrometry
KW - Molecular diagnostics
KW - Over the counter
KW - Point-of-care testing
UR - http://www.scopus.com/inward/record.url?scp=85122471710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122471710&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2021.12.011
DO - 10.1016/j.clinbiochem.2021.12.011
M3 - Article
AN - SCOPUS:85122471710
JO - Clinical Biochemistry
JF - Clinical Biochemistry
SN - 0009-9120
ER -